Joanne Parks, MD
Psychiatry · Barrington, ILNPI 1619019148
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $143,540 of the $162,875 with a category attached, or 88.1%. AbbVie accounts for 91.7% of it on its own, with 29 other manufacturers making up the rest. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $283.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$149K
- E.r. Squibb & Sons, L.L.C.$9K
- Lundbeck LLC$676
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$549
- Vanda Pharmaceuticals Inc.$483
- Otsuka America Pharmaceutical, Inc.$476
- plus $2K from 24 others
What the payments were for
- Consulting fees$7,2404%
- Speaking & faculty fees$143,54088%
- Travel & lodging$2,4301%
- Food & beverage$9,6166%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 336 | $149,296 |
| E.r. Squibb & Sons, L.L.C. | 17 | $8,953 |
| Lundbeck LLC | 43 | $676 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $549 |
| Vanda Pharmaceuticals Inc. | 19 | $483 |
| Otsuka America Pharmaceutical, Inc. | 26 | $476 |
| Axsome Therapeutics, Inc. | 7 | $330 |
| Alkermes, Inc. | 12 | $276 |
| Neuronetics, Inc. | 8 | $268 |
| Teva Pharmaceuticals USA, Inc. | 11 | $241 |
| Neurocrine Biosciences, Inc. | 7 | $180 |
| Harmony Biosciences LLC | 5 | $159 |
| Supernus Pharmaceuticals, Inc. | 7 | $142 |
| Sunovion Pharmaceuticals Inc. | 7 | $107 |
| Avanir Pharmaceuticals, Inc. | 6 | $94 |
| Johnson & Johnson | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $71 |
| Corium, LLC | 3 | $67 |
| Livanova USA, Inc. | 2 | $59 |
| Tris Pharma Inc | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| Shire North American Group Inc | 2 | $28 |
| Indivior Inc. | 2 | $26 |
| Neos Therapeutics, LP | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$144,829
- COBENFY$242
- NEUROSTAR TMS THERAPY$116
- Auvelity$111
How this compares
$162,875 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 123 | $268,849 |
| Austedo XrDeutetrabenazine | 12 | $115,703 |
| AptiomEslicarbazepine Acetate | 13 | $35,101 |
| CaplytaLumateperone Tosylate | 22 | $34,523 |
| TrintellixVortioxetine Hydrobromide | 14 | $22,015 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 99 | $17,134 |
| Aripiprazole | 95 | $9,926 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $7,122 |
| Quetiapine Fumarate | 187 | $5,866 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,105 |
| Duloxetine Hcl | 215 | $4,895 |
| Oxcarbazepine | 47 | $4,683 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $3,958 |
| Bupropion XlBupropion Hcl | 136 | $3,558 |
| Gabapentin | 145 | $3,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $149,296 | $268,849123 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $241 | $115,70312 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $107 | $35,10113 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $549 | $34,52322 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $76 | $27,11928 claims |
| OWP Pharmaceuticals, Inc.Subvenite | $15 | $93947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Barrington
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
- Nitin ThaparOrland Park$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.